Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Now, two new late-phase clinical trials, sponsored by Eli Lilly and Company, suggest that transitioning from high dose injectable weight loss medications to either a daily pill or a lower maintenance dose can help people living with obesity to keep off most of the weight they have already lost The results of the ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN trials were presented at the European Congress on Obesity and published in Previous research suggests that 1 year after stopping weight loss medication, people may regain, on average, 60% of their lost weight
Clinical trial data suggest that Mounjaro may produce greater weight loss than Wegovy, with the SURMOUNT-1 trial showing average reductions of 1522% of baseline body weight in non-diabetic adults with obesity, compared to 1015% with Wegovy in the STEP-1 trial, depending on the dose
None include retatrutide or any GLP-1 receptor agonist
Why cjc 1295 ipamorelin 5mg/5mg blend uk matters in 2026 Advanced cellular research and therapeutic studies are pushing more US labs toward high-purity synthetic options
Publicis Health Publicis Health provides marketing solutions for digital health brands with global reach
US$ 28.37
US$ 22.87
US$ 26.71
US$ 29.06
